Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.82 1.81

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.7199999999999998

Max

2.86

Belangrijke statistieken
By Trading Economics
Inkomsten	-27M -17M
EPS	-0.12
Winstmarge	-2,366.017
Werknemers	23
EBITDA	-4.7M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+123.21% upside

Dividenden
By Acuity
Volgende Winsten	11 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	6.2M 489M
Vorige openingsprijs	1.01
Vorige sluitingsprijs	2.82

Nieuwssentiment

By Acuity

67%

33%

302 / 340 Rangschikking in Healthcare

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 19:53 UTC

Social Media

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

13 aug 2026, 19:16 UTC

Social Media

News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12 aug 2026, 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7 aug 2026, 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6 aug 2026, 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5 aug 2026, 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4 aug 2026, 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3 aug 2026, 19:11 UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31 jul 2026, 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27 jul 2026, 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22 jul 2026, 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20 jul 2026, 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

123.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.25 USD 123.21%

Hoogste 9 USD

Laagste 4 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

302 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.